Yaël C. Cohen

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

OA-65 Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update

Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects

Pridopidine in early-stage manifest Huntington’s disease: a phase 3 trial

Multiple Myeloma Research and Treatments

Protein Degradation and Inhibitors

CAR-T cell therapy research

Peptidase Inhibition and Analysis

Amyloidosis: Diagnosis, Treatment, Outcomes